NewAmsterdam Pharma Company N.V. (NAMS) Operating margin 2022–2025
NewAmsterdam Pharma Company N.V. (NAMS) operating margin by fiscal year — reported operating income divided by reported revenue.
-1002.9%FY2025 · since FY2022: -3.5% → -1002.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1002.9% | -616.0 pp |
| FY2024 | -386.9% | +911.6 pp |
| FY2023 | -1298.6% | -1295.1 pp |
| FY2022 | -3.5% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More NAMS financial trends
NAMS RevenueNAMS Net incomeNAMS Net marginNAMS Gross profitNAMS Gross marginNAMS Operating incomeNAMS Operating cash flowNAMS Free cash flowNAMS Capital expendituresNAMS Return on equityNAMS Stock buybacksNAMS Dividends paidNAMS Total assetsNAMS Total liabilitiesNAMS Shareholders’ equityNAMS overview →